Future studies should focus on optimising delivery systems, exploring potential synergies with existing therapeutic regimens, and evaluating efficacy in related TLR4‐driven conditions such as sepsis‐induced acute respiratory distress syndrome (ARDS). The gene discussed is TLR4; the disease is Sepsis.